This may reflect the following mechanisms: (1) Aβ clearance requires multiple steps, such as synaptic remodeling and neuroinflammatory relief, to be translated into clinical benefits; (2) The continuous progression of tau pathology may offset the potential benefits of Aβ clearance; (3) The existing scales are not sensitive enough to capture the subtle changes in early AD. Here, MAPT is linked to Alzheimer disease.